A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|169|5|694-700

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.5, 2015-06, pp. : 694-700

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I/II study of oral clofarabine plus low‐dose cytarabine in previously treated acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients at least 60 years of age

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 3, 2015-08 ,pp. : 349-355

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib Treatment in 13 Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations in Combination with Chemotherapy or as Monotherapy

By  

Acta Haematologica, Vol. 124, Iss. 3, 2010-10 ,pp. : 153-159

Karger

Access to resources Recommend Favorite

FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia

By  

Acta Haematologica, Vol. 112, Iss. 1-2, 2004-06 ,pp. : 68-78

Karger

Access to resources Recommend Favorite

Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

By  

CANCER, Vol. 120, Iss. 14, 2014-07 ,pp. : 2142-2149

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 4, 2015-05 ,pp. : 534-543

John Wiley & Sons Inc

Access to resources Recommend Favorite